The CirCom score has been developed from Danish data as a specific measure of comorbidity for cirrhosis to predict all-cause mortality. We compared its performance with the Charlson Comorbidity Index (CCI) in an English cirrhosis population.
Introduction
Patients with cirrhosis have a high mortality. 1 Their high mortality is partly due to comorbidity, 2 so adjustment for differences in the burden of comorbidity is important in studies that compare mortality among these patients. This is similar to what has been shown in end-stage renal failure, heart failure, and chronic obstructive pulmonary disease (COPD). [3] [4] [5] For cirrhosis, Jepsen et al have developed a comorbidity score (CirCom) within a Danish cohort of patients with liver cirrhosis and shown it to be an improvement on the existing Charlson comorbidity score. 6 However, the accompanying commentary recommended further external validation that included calculation of absolute risks, as well as discrimination and model fit. 7 The most frequently validated method to date is the secondary care-derived CCI, published in 1987, 8 developed using hospital chart data of medical inpatients to predict mortality in the 1-year postdischarge and validated in a cohort of breast cancer inpatients. However, this score assessed all medical inpatients rather than those with specific disease, thus failing to recognize that the prognostic effect of a specific comorbid disease (eg, COPD) might depend on the index disease (eg, ischemic heart disease versus cirrhosis). Furthermore, the management and prognosis of various diseases have changed greatly over the last two decades altering what is relevant to be contained in a score. In contrast, CirCom was derived specifically for cirrhotic patients and reassessed which comorbidities were associated with mortality in this context. It is simpler in that it includes less comorbidities overall compared to the CCI, but with some different comorbidities such as substance abuse (other than alcohol use) and epilepsy. 6 We have previously extracted a validated and well-described cohort of cirrhotic patients with mixed etiology from linked primary care, secondary care, and death registry data within the Clinical Practice Research Datalink (CPRD). 9 The purpose of this validation study of the CirCom score within this English cohort is to assess the performance of CirCom compared to the CCI in predicting mortality. By doing this assessment, we hope to provide evidence for its use (or nonuse) as the preferred measure of comorbidity adjustment in future population-based observational studies on cirrhosis mortality.
Materials and methods Dataset
The CPRD consists of linked English Hospital Episodes Statistics data, primary care data, and the Office of National Statistics (ONS) death register. For this study, these data have linked records of all primary care events, hospital admissions, and causes of death from April 1997 to August 2010 for 3% of the English population (244 primary care practices).
Population
The cirrhosis cohort we used is one we have previously defined from the January 2011 static version of the CPRD (ISAC approved protocol number 09_065RA_4 and updated approval for this validation study 16_161). 9 It consists of 5118 patients who were ≥18 years and had a diagnostic code for cirrhosis or a therapeutic code for cirrhosis, esophageal varices, or portal hypertension within either primary care or secondary care data within the CPRD between January 1, 1998 and December 31, 2009 . These dates define the period when the linked data were available at the time of the initial study. The presence of cirrhosis was validated using secondary care, death registry, and free text data. 1 The study population was restricted to the 244 practices with the primary and secondary care linkages available within the January 2011 static version of the CPRD. For this cirrhosis cohort, the patient characteristics, etiology of the cirrhosis (alcohol, viral/autoimmune/metabolic, or unknown), cause of death, and 5-year survival have been well described. 1, 10 The observation period for patients within this cohort commenced on the latest of 1) 1 year after each patient's current registration date with an eligible practice, 2) the date that their practice's data were up to research standard, or 3) January 1, 1998, when the linkage of the CPRD to secondary care data was first available. The 1-year cutoff following registration was used to avoid including potential prevalent cases who were diagnosed before they were observable in the dataset. The period of observation in this cohort terminated for each patient on the earliest of 1) the date of their death, 2) the date the patient left the practice, 3) their practice's last data collection date, 4) the last date of the available linkage to secondary care (at the time of the study derivation) which was December 31, 2009 . Within this observation period, the start of each patient's follow-up was defined as his or her first Read or ICD 10 code for cirrhosis within the observation period. Patients with a diagnosis of cirrhosis before the observation period were excluded as the CirCom score was defined from comorbidity present at the time of diagnosis of cirrhosis. Follow-up for each patient ended at the end of the observation period described above.
Ethics
The CPRD has obtained ethical approval from the National Research Ethics Service Committee (NRECS) for all purely observational research using anonymized CPRD data. Studies which do not include patient involvement are reviewed for scientific quality by the Independent Scientific Advisory Committee for the Medicines and Healthcare Products Regulatory Agency database research. Regulatory approval for this study was obtained under approval 16_161. 
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CirCom score in an English cirrhosis population Sample size Studies modeling required sample sizes for complex discriminatory models have indicated that a study like ours requires at least 500 deaths, and ideally 1000. 11 Two thousand five hundred sixty-four deaths occurred within our liver cirrhosis cohort within the follow-up time providing sufficient power overall. Within the stratified analysis, there were more than 500 deaths in each of the etiology groups when defined as Viral/Autoimmune/Metabolic, Alcoholic, or Unspecified, and within each of the age categories defined below.
Comorbidity scores
We defined the CirCom score as described by Jepsen et al. 6 This score defines seven different weighted categories using ICD 10 codes. We also defined the CCI 8 to provide a comparison similar to Jepsen et al's paper. We used the Read and ICD 10 codes for the individual comorbidities that we have previously defined for calculating the CCI in linked primary and secondary care data within the CPRD. 12 The Read codes for these comorbidities were also used to define the comorbidities for the CirCom score, apart from substance abuse, epilepsy, and COPD. For the latter two of these categories, we used published code lists from www.clinicalcodes.org, 13, 14 and for substance abuse, the Read codes are listed in Table S1 . All comorbidities were defined using all diagnoses coded in the 5 years prior to the cirrhosis diagnosis date as was done in Jepsen et al's original paper. 6 Other covariates included etiology, cirrhosis stage, year of follow-up, socioeconomic status, age, and gender. For the stratified analysis, we used the age bands we published in our original cohort (<45, 45-54, 55-64, 65-74, >75 years). 10 Etiology was defined using the previously defined groups in the cohort as Alcoholic, Viral/Autoimmune/Metabolic, or Unspecified. Cirrhosis stage was defined as compensated or decompensated using the Baveno IV criteria already defined in the cohort. 1 Socioeconomic status was defined by quintile of deprivation as measured by the English Indices of Multiple Deprivation 2010. 15 Each year of follow-up from the first to the fifth year after cirrhosis diagnosis was defined, similar to our previously published work on comorbidity scores. 12 Finally, we used cirrhosis and non-cirrhosis death outcomes as already defined in this cohort from previous work on cause of death from the linked ONS Death Registry. 10 Specifically, we categorized deaths using the main ICD 10 chapter headings of K70-K77, C22, I85, I864, and I982 as liver related. This definition included bleeding from gastric and esophageal varices and hepatocellular carcinoma. All other ICD 10 codes were categorized as a non-liver death.
Statistical analysis
We described the cohort characteristics for each covariate to allow a comparison with numbers and proportions with the Danish Development cohort. We then fitted a Cox proportional hazards model including age, gender, and either the CCI as a categorical variable or the CirCom score as a categorical variable as in the Jepsen paper. To compare how well the Charlson and CirCom score models fitted the data, we calculated the Bayesian information criterion (BIC). This measure penalizes the likelihood of the model for the number of parameters it includes, and the model with the smaller BIC value is more likely to have a better fit. Discrimination was measured using the Harrell's C statistic, with 95% CIs calculated using the somersD command in Stata. 16 We calculated the predicted absolute 1-year mortality risk from each model using cumulative incidence functions. These absolute predicted mortality risks were used to classify patients into 1-year mortality probabilities of ≤20%, 21%-50%, and ≥51% to allow the net reclassification index (NRI) to be calculated. These were the categories used to assess the development of the CirCom score in the Danish cohort and were chosen to be clinically relevant. 6 To assess the calibration of the two scores, the observed 1-year mortality, computed using the Kaplan-Meier method, was plotted against the 1-year mortality predicted by the Cox model. 17 In addition, a decision curve analysis was performed assessing the net benefit of using each score compared to not using a score. The net benefit is calculated as the difference between the true positives (proportion of patients whose predicted risk was over a particular threshold who also died within 1 year of follow-up) and the false positives (proportion of patients whose predicted risk was over a particular threshold who did not die within 1 year of follow-up), for thresholds of predicted risk from 0% to 100%. 18 A stratified analysis was then performed to assess the models' discrimination by age, gender, socioeconomic status, cirrhosis etiology, cirrhosis stage, and follow-up year as defined above. A final analysis assessed the models' discrimination in predicting liver-related death and non-liver-related death separately.
Results

Validation population characteristics
The validation cirrhosis cohort from the CPRD had fewer patients than that used in Denmark for the score's development and a shorter median follow-up time (1.9 years compared to 2.8 years, respectively), but a similar median age (59 years compared to 58 years, respectively). The CPRD cohort had a 
110
Crooks et al lower proportion with alcohol as an etiology, a lower proportion of men, and a lower mortality. This was despite a higher proportion of patients in the CPRD who had a comorbidity that contributed to the Charlson or CirCom score (Table 1) .
Overall performance of comorbidity scores
The full models are shown for comparison in Table 2 . The CirCom score provided a better model fit than the CCI with an improvement in the BIC ( Table 2) .
Measures of discrimination of the CCI and CirCom score models are shown in Table 3 compared to models with age and sex alone. Both scores showed an improvement when compared to age and sex alone with a small improvement in the C statistic from the model using the CirCom score compared to the CCI. This was also reflected in the 1.5% improvement of the CirCom score over the CCI in classifying 1-year mortality as measured by the categorical NRI (see Table 3 ). The addition of a covariate for decompensated or compensated liver disease further increased the 
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CirCom score in an English cirrhosis population discrimination of the model containing the CirCom score (C=0.67, 95% confidence interval [0.66-0.68]). Calibration was similar between the two scores ( Figure S1 ). The decision curve analysis showed similar results for both scores, with a net benefit in true over false positives when the threshold used for the predicted risk of 1-year mortality was between 20% and 60% for both the CCI and the CirCom score ( Figure S2 ).
To assess whether the differences in performance were due to difference in numbers of parameters, we reassessed the CCI score collapsed to 0, 1, 2, 3, 4, and 5 or more. This reduced the BIC for the CCI to 40,369, but this was still greater than the BIC for the CirCom score (which remained the better fit). The discrimination for the CCI with only six parameters was not altered (C statistic=0.62 [0.61-0.63]). 
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Stratified analysis
The CirCom score conferred a slight improvement in discrimination over the CCI in younger age groups, particularly in the <45-year-old age group (Table 4) . Among the subgroups defined by cirrhosis etiology, the difference between the CCI and the CirCom score was most notable in the subgroup with alcoholic cirrhosis (Table 5 ). Both comorbidity scores performed better in those with autoimmune, viral, metabolic, or unknown causes, which reflected the older mean age in these groups and resultant higher prevalence of comorbidity. There was also a slight improvement in discrimination of the CirCom score over the CCI in those with compensated cirrhosis at presentation, but not in those with decompensated cirrhosis. The CirCom score performed better than the CCI in the first year of follow-up with similar discrimination in the subsequent years (Table 6 ). Discrimination reduced with increasing deprivation, but there was less of a reduction for the CirCom score (Table S2 ).
Both comorbidity scores had identically poor discrimination for liver-related death and identically good discrimination for non-liver-related death. The inclusion of a measure of decompensation improved the discrimination of a model with either score for liver-related death (Table 7) .
Discussion
The CirCom score provided a small improvement in performance over the CCI when used to predict mortality in a large, population-based cohort of patients with cirrhosis of mixed etiology. Both scores showed good discriminative ability to predict deaths not related to the liver, which were almost half of the deaths, but poor ability to predict deaths related to the liver. However, the purpose of a comorbidity score is to adjust for factors other than the severity of cirrhosis and in this context it performs. Both the CCI and the CirCom score improved the performance of the model over using just demographic information, emphasizing 
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CirCom score in an English cirrhosis population the importance of including a comorbidity measure in any comparative study of cirrhosis survival. In particular, this validation study supports the use of the CirCom score as a measure of non-cirrhosis-related or all-cause mortality in cirrhotic patients in the English population. The importance of our work is not just that it shows the utility of the score in an international context beyond Denmark, but that it also shows that the score is translatable into other coding systems such as the Read codes used in the CPRD. Furthermore, the Danish data use secondary care outpatient data for longitudinal comorbidity coding, whereas the English data use both linked inpatient secondary care and general practitioner primary care comorbidity coding. The finding that the score showed a consistent improvement over the CCI in this different health care context confirms the score's generalizability, particularly as we demonstrated an even greater improvement in the C statistic than in the original Danish derivation cohort.
The strengths of this study are that it provides an indepth analysis of the performance of the CirCom score and the CCI in an English population. The English CPRD has extensive linkages, and these have allowed the current cohort to be validated and its characteristics comprehensively described.
1,9,10 Therefore, we are confident of the validity of the cirrhosis diagnosis from the primary and secondary care data, and the recording of death from the national death registry. Furthermore, the recording of comorbidity in the CPRD has previously been validated against anonymized case records in many studies (myocardial infarction, 19, 20 heart failure, 21, 22 cerebrovascular disease, [23] [24] [25] dementia, 26, 27 respiratory disease, [28] [29] [30] connective tissue disease, 31-34 peptic ulcers, 35 liver disease, 9,36 renal failure, 37 cancer, 38 leukemia, and lymphoma 39 ), and the sensitivity of definitions improved when defined from linked primary and secondary care records (eg, diabetes, 40, 41 cirrhosis, 9 and acute myocardial infarction 42 ). The Model for End-Stage Liver Disease and the ChildPugh score outperformed both the CCI and the CirCom score in predicting cirrhosis survival in a US Veteran cohort, 43 and the validation in the original CirCom score paper showed the same. 6 However, these measures depend on laboratory values that were not available in the CPRD. We have previously shown that it was possible to derive a measure of cirrhosis stage using just diagnostic coding within the CPRD, 9 and including this as a variable for decompensation in our current study greatly improved the discrimination for liver-related death, and consequently the overall discrimination of allcause mortality for our model with the CirCom score. The value of a comorbidity score, therefore, is that it predicts the additional non-liver-related outcomes that are not predicted by measures of severity of cirrhosis, and it will have benefit when added to any measure of cirrhosis severity.
The higher prevalence of comorbidity in the English cohort compared to the Danish cohort might reflect the more extensive comorbidity coding in a comprehensive primary care system in the UK or might reflect the more varied etiology of the English cohort, which had a lower proportion with alcohol etiology. We have previously shown that those patients with a non-alcohol etiology survive longer than those with an alcohol etiology, and, therefore, will have had a longer period of care in which to develop comorbidities and nonliver-related deaths. 44 Finally, within the English cohort, the improvement with the CirCom score over the CCI was most noticeable in younger patients and in those with an alcohol etiology. This likely reflects the inclusion of epilepsy and substance abuse that have more importance in a cirrhotic cohort because of their association with a more hazardous lifestyle. 45 
Conclusion
We have validated the CirCom score in the English-linked CPRD as a measure of the burden of comorbidity and found that its performance is better than the CCI. However, both the CCI and the CirCom score improved discrimination compared to a model containing only age and sex. This emphasizes the importance of including any measure of comorbidity in comparative studies of cirrhosis survival. 
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Read code Description
E259000
Nondependent mixed drug abuse, unspecified E259100 Nondependent mixed drug abuse, continuous E259200 Nondependent mixed drug abuse, episodic E259300 Nondependent mixed drug abuse in remission E259z00
Nondependent mixed drug abuse NOS E25y.00
Nondependent other drug abuse E25y000
Nondependent other drug abuse, unspecified E25y100
Nondependent other drug abuse, continuous E25y200
Nondependent other drug abuse, episodic E25y300
Nondependent other drug abuse in remission E25yz00
Nondependent other drug abuse NOS Eu11212
Heroin addiction Eu14.00
Mental and behavioral disorders due to use of cocaine Eu14000
Mental and behavior disorder due to use cocaine: acute intoxication Eu14100
Mental and behavior disorder due to use of cocaine: harmful use Eu14200
Mental and behavior disorder due to use of cocaine: dependence syndrome Eu14211
Drug addiction -cocaine Eu14300
Mental and behavior disorder due to use of cocaine: withdrawal state Eu14500
Mental and behavior disorder due to use of cocaine: psychotic disorder Eu1A.00
Mental and behavioral disorders due to use of crack cocaine Eu1A000
Mental and behavioral disorders due to use of crack cocaine: acute intoxication Eu1A100
Mental and behavioral disorders due to use of crack cocaine: harmful use Eu1Az00
Mental and behavioral disorders due to use of crack cocaine: unspecified mental and behavioral disorder R10B000
Finding of cocaine in blood SL50100
Heroin poisoning SL85000
Cocaine poisoning TJ85000 Adverse reaction to cocaine U205.11
Overdose -heroin U608312 Adverse reaction to cocaine Z1Q6214 Heroin maintenance ZC16.00
Abuse of drugs to lose weight ZV11500 Personal history of drug abuse by injection ZV6D700 Drug abuse counseling and surveillance
Abbreviations: H/O, history of; NOS, not otherwise specified. 
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